Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2012

01-05-2012 | Regional Cancer Therapies

Concepts of Regional Therapies for Advanced Malignancy

Authors: T. Clark Gamblin, MD, H. Richard Alexander, MD, Robert Edwards, MD, David L. Bartlett, MD

Published in: Annals of Surgical Oncology | Issue 5/2012

Login to get access

Excerpt

Management approaches for regionally advanced cancers include cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), isolated limb infusion and perfusion, isolated liver perfusion, hepatic artery directed therapies, and other novel therapies, such as thoracic and pelvic perfusion. Surgical oncologists are incorporating these approaches with increasing frequency worldwide as safety, morbidity rate, and therapeutic considerations are better understood.1 These advances in regional treatment options have challenged the staging systems, examined the quality of life associated with treatment, and sought to improve patient survival for diseases with limited options. Recent improvements in the understanding of tumor biology have allowed for improved selection, and in some cases a shift from palliative to a curative intent. …
Literature
1.
Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128–33.PubMed
2.
3.
Beasley GM, Caudle A, Petersen RP, et al. A multiinstitutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208(5):706–15.PubMedCrossRef
4.
5.
Winder T, Lenz HJ. Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy. Oncologist. 2010;15(8):836–44.PubMedCrossRef
6.
Salti GI, Ailabouni L, Undevia S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis. Ann Surg Oncol. 2012. doi:10.​1245/​s10434-012-2240-7.
7.
Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2012. doi:10.​1245/​s10434-012-2236-3.
8.
Koh JL, Tan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:327–33.PubMedCrossRef
9.
Choudry HA, Mavanur A, O’Malley ME, et al. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei. Ann Surg Oncol. 2012. doi:10.​1245/​s10434-012-2242-5.
10.
Mavanur AA, Parimi V, O’Malley M, Nikiforova M, Bartlett DL, Davison JM. Establishment and characterization of a murine xenograft model of appendiceal mucinous adenocarcinoma. Int J Exp Pathol. 2010;91(4):357–67.PubMedCrossRef
11.
Austin F, Mavanur A, Sathaiah M, et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol. 2012. doi:10.​1245/​s10434-012-2241-6.
12.
Baratti D, Kusamura S, Cabras AD, et al. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: A controlled study. Ann Surg Oncol. 2012. doi:10.​1245/​s10434-012-2237-2.
13.
Rossi CR, Casali P, Kusamura S, Baratti D, Deraco M. The consensus statement on the locoregional treatment of abdominal sarcomatosis. J Surg Oncol. 2008;98(4):291–4.PubMedCrossRef
14.
Metadata
Title
Concepts of Regional Therapies for Advanced Malignancy
Authors
T. Clark Gamblin, MD
H. Richard Alexander, MD
Robert Edwards, MD
David L. Bartlett, MD
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 5/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2243-4

Other articles of this Issue 5/2012

Annals of Surgical Oncology 5/2012 Go to the issue

Breast Oncology

Clinical and Self Breast Examination Remain Important in the Era of Modern Screening

Hepatobiliary Tumors

Oncological Superiority of Hilar En Bloc Resection for the Treatment of Hilar Cholangiocarcinoma

Translational Research and Biomarkers

Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer

Breast Oncology

Scoring System Based on BI-RADS Lexicon to Predict Probability of Malignancy in Suspicious Microcalcifications

Thoracic Oncology

Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy

Endocrine Tumors

Is One Benign Fine Needle Aspiration Enough?